Data Bridge Market Research analyses that the Pregabalin Market was valued at USD 769.47 million in 2021 and is expected to reach USD 596.65 billion by 2029, registering a CAGR of 3.53% during the forecast period of 2022 to 2029.

Industry Analysis

Pregabalin is an anticonvulsant medication that can be used to treat epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. It works by reducing the pain signals delivered by injured nerves throughout the body. As per the International Association of the Study of Pain's Global Year against Neuropathic Pain 2014-2015 study, approximately 7% to 8% of adults suffer from chronic pain with neuropathic characteristics. Furthermore, the patent expiration of Pfizers' Lyrica (Pregabalin) in 2018 is expected to boost generic manufacturing manufacturers' market share in the U.K.

In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Pregabalin is an anticonvulsant and anxiolytic medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome, and generalized anxiety disorder. It's an epilepsy medication that's used to treat partial seizures. It functions by lowering nerve activity and lowers pain. Anti-epileptic medicines (AEDs) such as Lyrica (pregabalin) and Topamax (topiramate) are used to prevent epileptic seizures. Lyrica is also indicated to treat diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia neuropathic pain.

Get the sample copy of the report here: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pregabalin-market

Global Pregabalin Market Scope

The pregabalin market is segmented on the basis of drug class, application, dosage forms, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Application

·       Epilepsy

·       Neuropathic Pain

·       Anxiety Disorder

·       Others

Drug Class

·       Fibromyalgia Agents

·       Anticonvulsants

·       Others

Dosage Forms

·       Oral Capsule

·       100 mg

·       150 mg

·       200 mg

·       225 mg

·       25 mg

·       300 mg

·       50 mg

·       75 mg

 

·       Oral Solution

·       20 mg/mL

 

·       Oral Tablet, extended release

·       165 mg

·       330 mg

·       82.5 mg

End-Users

·       Hospitals

·       Specialty Clinics

·       Homecare

·       Others

Distribution Channel

·       Hospital Pharmacy

·       Retail Pharmacy

·       Online Pharmacy

·       Others

Get TOC Details: https://www.databridgemarketresearch.com/toc/?dbmr=global-pregabalin-market

Pregabalin Market Regional Analysis/Insights

The pregabalin market is analysed and market size insights and trends are provided by country, drug class, application, dosage forms, end-users and distribution channel as referenced above.

The countries covered in the pregabalin market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the pregabalin market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, an increase in the number of research and development activities will further propel themarket's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to surging prevalence of convulsions and anxiety disorders in this region. Also, the development of healthcare infrastructure and rising geriatric population will further propel themarket's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Pregabalin Market Share Analysis

The pregabalin market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pregabalin market.

Some of the major players operating in the pregabalin market are:

·       Pfizer Inc. (US)

·       GlaxoSmithKline plc (UK)

·       Novartis AG (Switzerland)

·       Mylan N.V. (US)

·       Teva Pharmaceutical Industries Ltd. (Israel)

·       Sanofi (France)

·       F. Hoffmann-La Roche Ltd. (Switzerland)

·       Aurobindo Pharma (India)

·       Lupin (India)

·       Zydus Cadila (India)

·       Amneal Pharmaceuticals LLC. (US)

·       Cipla Inc. (US)

·       Torrent Pharmaceuticals Ltd. (India)

·       Glenmark Pharmaceuticals Limited (India)

·       Medley Pharmaceuticals Ltd. (India)

·       Genesis Biotec Inc. (India)

·       Biomax Pharmaceutical Company (UK)

·       ZCL Chemicals Ltd. (India)

·       Olon S.p.A. (Italy)

·       HIKAL Ltd. (India)

Get Full Access of reports @ https://www.databridgemarketresearch.com/reports/global-pregabalin-market

MAJOR TOC OF THE REPORT

Ø  Chapter One: Introduction

Ø  Chapter Two: Market Segmentation

Ø  Chapter Three: Market Overview

Ø  Chapter Four: Executive Summary

Ø  Chapter Five: Premium Insights

Ø  Chapter Six: Global Pregabalin Market by Product & Procedure type

Browse Related Reports @

https://www.databridgemarketresearch.com/reports/global-stretchers-market

https://www.databridgemarketresearch.com/reports/global-medical-oxygen-concentrators-and-oxygen-cylinders-market

https://www.databridgemarketresearch.com/reports/global-hair-transplant-market

https://www.databridgemarketresearch.com/reports/global-mens-health-market

https://www.databridgemarketresearch.com/reports/global-induced-pluripotent-stem-cells-market

About Us:-
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:-
Data Bridge Market Research
Tel: +1-888-387-2818  
Email: Sopan.gedam@databridgemarketresearch.com